ERYtech Pharma creates high value products for hospital market, mainly in oncology, hematology and immunology fields.
ERYtech Pharma has a first success with its lead compound Graspa® which demonstrated positive results and excellent safety profile compared to control treatment in Phase II trials in acute lymphoblastic leukaemia. Phase III in leukaemia started in 2009 and a development program of Graspa® in several other indications notably solid tumors is ongoing.
Headquartered in France (Lyon) with a cGMP manufacturing unit, ERYtech Pharma has a US Office and a US location for cGMP clinical batches production at the American Red Cross.
ERYtech Pharma’s business & revenue model is both:
- An integrated business & revenue model for proprietary product to maximize value creation
- A business development revenue model based on its R&D platform and partnership
Main achievements and highlights:
2010
- Agreement with M. D. Anderson Cancer Center to develop a companion test for Graspa® in solid tumors
- FDA grants Orphan Drug Designation to Graspa® for treatment of Acute Lymphoblastic Leukaemia
2009
- Pivotal Clinical Trial for Graspa® in Acute Lymphoblastic Leukaemia in Europe
- Phase II Clinical Trial with Graspa® as first-line treatment among patients with Acute Lymphoblastic Leukaemia aged 55 and older
- cGMP facility certification from the French Health Products Safety Agency (AFSSAPS)
- American Red Cross manufacturing and supply agreements
- ISO 9001:2008 certification
- Granted by the French Ministry of Research
- Supervisory Board and Scientific Board reinforced
2008
- Phase I/II Clinical Trial for Graspa® last patient enrolled and results presented at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco
- Granted by France's National Research Agency and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA)
2007
- Phase I/II Clinical Trial for Graspa®: launching in Belgium
- New Headquarters, R&D laboratory and cGMP facility in Lyon
2006
- Phase I/II Clinical Trial for Graspa®: first patient enrolled
- EMEA awards Medicinal Product classification for Graspa®
- EMEA awards Orphan Drug Designation for Graspa®
- Financing round A € 12 million
2005
- Seed Financing Round € 750.000 with financial shareholders and business angels
- Granted by the French Ministry of Research, France's National Research Agency, Rhône-Alpes Région and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA)
2004
- ERYtech Pharma incorporation
- Granted by the French Ministry of Research and award from the Rhône-Alpes Ouest Créalys business incubator
